†Present address: The Binding Site, Inc., San Diego, CA, USA.
‡Present address: Department of Medical Hygiene Technology, Kochi Gakuen College, Kochi prefecture, 780-0955, Japan.
§Present address: Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
The dengue virus (DENV) envelope protein domain 3 (ED3) is the target of potent virus neutralizing antibodies. The DENV-2 ED3 contains adjacent type-specific and DENV complex-reactive antigenic sites that are composed of a small number of residues that were previously demonstrated to be critical for antibody binding. Site-directed mutagenesis of a DENV-2 16681 infectious clone was used to mutate critical residues in the DENV-2 type-specific (K305A and P384A) and DENV complex-reactive (K310A) antigenic sites. The K305A mutant virus multiplied like the parent virus in mosquito and mammalian cells, as did the P384A mutant virus, which required a compensatory mutation (G330D) for viability. However, the K310A mutant virus could not be recovered. The DENV-2 type-specific critical residue mutations K305A and P384A+G330D reduced the ability of DENV-2 type-specific, but not DENV complex-reactive, mAbs to neutralize virus infectivity and this was directly correlated with mAb binding affinity to the rED3 mutants.
ChenY., MaguireT., HilemanR. E., FrommJ. R., EskoJ. D., LinhardtR. J., MarksR. M.1997; Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 3:866–871 [View Article][PubMed]
ErbS. M., ButrapetS., MossK. J., LuyB. E., ChildersT., CalvertA. E., SilengoS. J., RoehrigJ. T., HuangC. Y., BlairC. D.2010; Domain-III FG loop of the dengue virus type 2 envelope protein is important for infection of mammalian cells and Aedes aegypti mosquitoes. Virology 406:328–335 [View Article][PubMed]
FibriansahG., TanJ. L., SmithS. A., de AlwisA. R., NgT. S., KostyuchenkoV. A., IbarraK. D., WangJ., HarrisE. et al.2014; A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol Med 6:358–371 [View Article][PubMed]
GromowskiG. D., BarrettA. D.2007; Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366:349–360 [View Article][PubMed]
GromowskiG. D., BarrettN. D., BarrettA. D.2008; Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol 82:8828–8837 [View Article][PubMed]
GromowskiG. D., RoehrigJ. T., DiamondM. S., LeeJ. C., PitcherT. J., BarrettA. D.2010; Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape. Virology 407:237–246 [View Article][PubMed]
HuangC. Y., ButrapetS., MossK. J., ChildersT., ErbS. M., CalvertA. E., SilengoS. J., KinneyR. M., BlairC. D., RoehrigJ. T.2010; The dengue virus type 2 envelope protein fusion peptide is essential for membrane fusion. Virology 396:305–315 [View Article][PubMed]
HungJ. J., HsiehM. T., YoungM. J., KaoC. L., KingC. C., ChangW.2004; An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells. J Virol 78:378–388 [View Article][PubMed]
KinneyR. M., ButrapetS., ChangG. J., TsuchiyaK. R., RoehrigJ. T., BhamarapravatiN., GublerD. J.1997; Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 230:300–308 [View Article][PubMed]
ModisY., OgataS., ClementsD., HarrisonS. C.2003; A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 100:6986–6991 [View Article][PubMed]
PitcherT. J., GromowskiG. D., BeasleyD. W., BarrettA. D.2012; Conservation of the DENV-2 type-specific and DEN complex-reactive antigenic sites among DENV-2 genotypes. Virology 422:386–392 [View Article][PubMed]
RoehrigJ. T., BolinR. A., KellyR. G.1998; Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246:317–328 [View Article][PubMed]
RoehrigJ. T., ButrapetS., LissN. M., BennettS. L., LuyB. E., ChildersT., BoroughsK. L., StovallJ. L., CalvertA. E. et al.2013; Mutation of the dengue virus type 2 envelope protein heparan sulfate binding sites or the domain III lateral ridge blocks replication in Vero cells prior to membrane fusion. Virology 441:114–125 [View Article][PubMed]
SmithS. A., de AlwisR., KoseN., DurbinA. P., WhiteheadS. S., de SilvaA. M., CroweJ. E.Jr2013; Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. J Infect Dis 207:1898–1908 [View Article][PubMed]
Sukupolvi-PettyS., AustinS. K., PurthaW. E., OliphantT., NybakkenG. E., SchlesingerJ. J., RoehrigJ. T., GromowskiG. D., BarrettA. D. et al.2007; Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 81:12816–12826 [View Article][PubMed]
Sukupolvi-PettyS., AustinS. K., EngleM., BrienJ. D., DowdK. A., WilliamsK. L., JohnsonS., Rico-HesseR., HarrisE. et al.2010; Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol 84:9227–9239 [View Article][PubMed]
WahalaW. M., HuangC., ButrapetS., WhiteL. J., de SilvaA. M.2012; Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera. J Virol 86:4019–4023 [View Article][PubMed]